Evolution of Coronavirus Disease 2019 (COVID-19) Symptoms During the First 12 Months After Illness Onset

Elke Wynberg, Hugo D G van Willigen, Maartje Dijkstra, Anders Boyd, Neeltje A Kootstra, Joost G van den Aardweg, Marit J van Gils, Amy Matser, Marije R de Wit, Tjalling Leenstra, Godelieve de Bree, Menno D de Jong, Maria Prins, RECoVERED Study Group, Ivette Agard, Jane Ayal, Floor Cavdar, Marianne Craanen, Udi Davidovich, Annemarieke Deuring, Annelies van Dijk, Ertan Ersan, Laura Del Grande, Joost Hartman, Nelleke Koedoot, Romy Lebbink, Dominique Loomans, Agata Makowska, Tom du Maine, Ilja de Man, Lizenka van der Meij, Marleen van Polanen, Maria Oud, Clark Reid, Leeann Storey, Marc van Wijk, Elke Wynberg, Hugo D G van Willigen, Maartje Dijkstra, Anders Boyd, Neeltje A Kootstra, Joost G van den Aardweg, Marit J van Gils, Amy Matser, Marije R de Wit, Tjalling Leenstra, Godelieve de Bree, Menno D de Jong, Maria Prins, RECoVERED Study Group, Ivette Agard, Jane Ayal, Floor Cavdar, Marianne Craanen, Udi Davidovich, Annemarieke Deuring, Annelies van Dijk, Ertan Ersan, Laura Del Grande, Joost Hartman, Nelleke Koedoot, Romy Lebbink, Dominique Loomans, Agata Makowska, Tom du Maine, Ilja de Man, Lizenka van der Meij, Marleen van Polanen, Maria Oud, Clark Reid, Leeann Storey, Marc van Wijk

Abstract

Background: Few robust longitudinal data on long-term coronavirus disease 2019 (COVID-19) symptoms are available. We evaluated symptom onset, severity and recovery across the full spectrum of disease severity, up to one year after illness onset.

Methods: The RECoVERED Study is a prospective cohort study based in Amsterdam, the Netherlands. Participants aged ≥18 years were enrolled following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnosis via the local public health service and from hospitals. Standardized symptom questionnaires were completed at enrollment, 1 week and month later, and monthly thereafter. Clinical severity was defined according to World Health Organization (WHO) criteria. Kaplan-Meier methods were used to compare time from illness onset to symptom recovery, by clinical severity. We examined determinants of time to recovery using multivariable Cox proportional hazards models.

Results: Between 11 May 2020 and 1 May 2021, 342 COVID-19 patients (192 [56%] male) were enrolled, of whom 99/342 (29%) had mild, 145/342 (42%) moderate, 56/342 (16%) severe, and 42/342 (12%) critical disease. The proportion of participants who reported at least 1 persistent symptom at 12 weeks after illness onset was greater in those with severe/critical disease (86.7% [95% confidence interval {CI} = 76.5-92.7%]) compared to those with mild or moderate disease (30.7% [95% CI = 21.1-40.9%] and 63.8% [95% CI = 54.8-71.5%], respectively). At 12 months after illness onset, two-fifths of participants (40.7% [95% CI = 34.2-7.1]) continued to report ≥1 symptom. Recovery was slower in female compared to male participants (adjusted hazard ratio [aHR] 0.65 [95% CI = .47-.92]) and those with a body mass index [BMI] ≥30kg/m2 compared to BMI <25kg/m2 (hazard ratio [HR] 0.62 [95% CI = .39-.97]).

Conclusions: COVID-19 symptoms persisted for one year after illness onset, even in some individuals with mild disease. Female sex and obesity were the most important determinants of speed of recovery from symptoms.

Keywords: Long COVID; recovery; symptoms.

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Kaplan-Meier estimates of time from illness onset to complete recovery from symptoms, by clinical severity group. Clinical severity groups of severe and critically severe COVID-19 combined due to small numbers. Dashed red vertical line denotes 12 weeks (cutoff point for post-COVID syndrome, as per NICE definition); black vertical lines indicate time-points at which participants were censored. Participants who were vaccinated while still having symptoms (n = 91, median time from onset of symptoms to vaccination 249 days [IQR 142-365]) were right-censored at date of first vaccination. Curves represent the percentages of study participants recovering from symptoms during 1 year after COVID-19 illness onset. Shaded areas represent 95% CIs. The numbers of individuals at risk during each 28-day interval since illness onset are given below the graph. Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; NICE, National Institute for Health and Care Excellence.
Figure 2.
Figure 2.
Unadjusted and adjusted hazard ratios of time to complete recovery for age, sex, BMI, and number of comorbidities at illness onset. Comorbidities counted are those listed by the WHO as being associated with a higher risk of developing severe or critical COVID-19 [11, excluding BMI]. BMI categorized in kg/m2 as: <25, underweight or normal weight; 25 up to 30, overweight; >30, obese. P-value calculated using likelihood ratio test. Abbreviations: aHR, adjusted hazard ratio; BMI, body mass index; CI, confidence interval; COVID-19, coronavirus disease 2019; HR, hazard ratio; WHO, World Health Organization.

References

    1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 324:782–93.
    1. Guan W-j, Ni Z-y, Hu Y, et al. . Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708–20.
    1. Chen T, Wu D, Chen H, et al. . Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. (1756–1833 [Electronic]).
    1. Huang C, Wang Y, Li X, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497–506.
    1. Huang C, Huang L, Wang Y, et al. . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397:220–32.
    1. Morin L, Savale L, Pham T, et al. . Four-month clinical status of a cohort of patients after hospitalization for COVID-19. (1538-3598 [Electronic]).
    1. Boscolo-Rizzo P, Guida F, Polesel J, et al. . Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19). Int Forum Allerg Rhinol 2021: 1–4. Available at: 10.1002/alr.22832.
    1. Logue JK, Franko NM, McCulloch DJ, et al. . Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open 2021; 4:e210830.
    1. BodyPolitic. About us. . Accessed 7 June 2021.
    1. Calvo-Bonacho E, Catalina-Romero C, Fernández-Labandera C, et al. . COVID-19 and sick leave: an analysis of the Ibermutua cohort of over 1,651,305 Spanish workers in the first trimester of 2020. (2296–2565 [Print]).
    1. Chen SI, Pierri N, Presbitero AF. Tracking the economic impact of COVID-19 and mitigation policies in Europe and the United States. IMF Working Papers 2020; (Working Paper No. 20/125).
    1. RIVM. Status validatie SARS-CoV-2 antigeensneltesten. In: Infectieziektebestrijding C. 19 July 2021 ed. Bilthoven: RIVM, 2021.
    1. GeurtsvanKessel CH, Okba NMA, Igloi Z, et al. . An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat Commun 2020; 11:3436.
    1. ISARIC. Clinical data collection – the COVID-19 case report forms (CRFs). . Accessed 18 April 2020.
    1. National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the long-term effects of COVID-19 NG188. Vol. 2021. London: NICE, 2021.
    1. World Health Organization (WHO). Clinical management of COVID-19. WHO Headquarters (HQ). World Health Organization, 2021.
    1. Council. MR. MRC Dyspnoea scale/MRC Breathlessness scale. . Accessed 18 April 2020.
    1. Stronks K, Kulu-Glasgow I, Agyemang C. The utility of ‘country of birth’ for the classification of ethnic groups in health research: the Dutch experience. Ethn Health 2009; 14:255–69.
    1. Sigfrid L, Drake TM, Pauley E, et al. . Long Covid in adults discharged from UK hospitals after Covid-19: a prospective, multicentre cohort study using the ISARIC WHO clinical characterisation protocol. medRxiv 2021. Doi: 10.1101/2021.03.18.21253888.
    1. Ayoubkhani DG. Update on long COVID prevalence estimate.. Accessed 8 April 2021.
    1. Havervall S, Rosell A, Phillipson M, et al. . Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA 2021; 325:2015–6.
    1. Nature. Long COVID: let patients help define long-lasting COVID symptoms. Nature 2020; 586: 170.
    1. RIVM. Long COVID. . Accessed 6 April.
    1. McLaren L. Socioeconomic status and obesity. Epidemiol Rev 2007; 29: 29–48.
    1. Kompaniyets LGA, Belay B, Freedman D, et al. . Body mass index and risk for COVID-19–related hospitalization, intensive care unit admission, invasive mechanical ventilation, and death—United States, March–December 2020. 2021.
    1. Sabes-Figuera R, McCrone P, Hurley M, King M, Donaldson AN, Ridsdale L. The hidden cost of chronic fatigue to patients and their families. BMC Health Serv Res 2010; 10:56.
    1. Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? Lung 2021; 199:113–9.
    1. Coyer L, Wynberg E, Buster M, et al. . Hospitalisation rates differed by city district and ethnicity during the first wave of COVID-19 in Amsterdam, the Netherlands. medRxiv 2021. doi: 10.1101/2021.03.15.21253597.
    1. Coyer L, Boyd A, Schinkel J, et al. . SARS-CoV-2 antibody prevalence and determinants of six ethnic groups living in Amsterdam, the Netherlands: a population-based cross-sectional study, June–October 2020. medRxiv 2021. doi: 10.1101/2021.03.08.21252788.
    1. Jewell BL. Monitoring differences between the SARS-CoV-2 B.1.1.7 variant and other lineages. Lancet Public Health 2021; 6:e267–8.

Source: PubMed

3
Abonnieren